UFT plus oral leucovorin: A new oral treatment for colorectal cancer

Oncologist

Volumn 3, Issue 3, 1998, Pages 155-164

  Hoff, Paulo M ^a   Pazdur, Richard ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

5 fluorouracil; Colorectal cancer; Leucovorin; Tegafur; UFT; Uracil

Indexed keywords

FLUOROURACIL; FOLINIC ACID; TEGAFUR; UFT;

ANOREXIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG RESPONSE; FATIGUE; GASTROINTESTINAL SYMPTOM; HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

EID: 0031750330     PISSN: 10837159     EISSN: None     Source Type: Journal    
DOI: 10.1634/theoncologist.3-3-155     Document Type: Article

References (15)

1. Fujii S, Ikenaka K, Fukushima M et al. Effect of uracil and its derivatives on antitumor activity of 5-fluorouracil 1-(2-tetrahydryofuryl)-5-fluorouracil. Gann 1978;69:763-772.
2. Fujii S, Kitano S, Ikenaka K et al. Studies on coadministration of uracil or cytosine on antitumor activity of FT-207 or 5-FU derivatives. Jpn J Cancer Chemother 1979;6:377-384.
3. Buroker T, Padilla F, Groppe C et al. Phase II evaluation of ftorafur in previously untreated colorectal cancer: a Southwest Oncology Group study. Cancer 1979;44:48-51.
4. Friedman MA, Ignoffo RJ. A review of the United States clinical experience of the fluoropyridimine, ftorafur (NSC-148958). Cancer Treat Rev 1980;7:205-213.
5. 1--2′-furanidyl-5-fluorouracil). Cancer Res 1976;36:1821-1824.
6. Ansfield FJ, Kallas GJ, Singson JP. Phase I-II studies of oral tegafur (ftorafur). J Clin Oncol 1983;1:107-110.
7. Taguchi T. Clinical application of biochemical modulation in cancer chemotherapy: biochemical modulation of 5-FU. Oncology 1997;54(suppl 1):12-18.
8. Watanabe H, Yamamoto S, Naito T. Clinical results of oral UFT therapy under cooperative study. Jpn J Cancer Chemother 1980;7:1588-1596.
9. Pazdur R, Lassere Y, Diaz-Canton E et al. Phase I trial of uraciltegafur (UFT) plus oral leucovorin: 14-day schedule. Invest New Drugs 1997;15:123-129.
10. Leichman CG, Fleming TR, Muggia FM et al. Phase II study of fluorouracil and its modulation in advanced colorectal cancer: a Southwest Oncology Group study. J Clin Oncol 1995;13:1303-1311.
11. Lokich JJ, Ahlgren JD, Gullo JJ et al. A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal cancer. A Mid-Atlantic Oncology Program study. J Clin Oncol 1989;7:425-432.
12. The Meta-analysis Group in Cancer. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol 1998;16:301-308.
13. Arbuck S. Overview of clinical trials using 5-fluorouracil and leucovorin for the treatment of colorectal cancer. Cancer 1989;63(suppl 6):1036-1044.
14. Poon MA, O'Connell MJ, Moertel CG et al. Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma. J Clin Oncol 1989;7:1407-1417.
15. Rustum YM. Toxicity and antitumor activity of 5-fluorouracil in combination with leucovorin. Role of dose, schedule, and route of administration of leucovorin. Cancer 1989;63(suppl 6):1013-1017.